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Divergent effects of ﬁrst-generation and
second-generation antipsychotics on cortical
thickness in ﬁrst-episode psychosis
B. R. E. Ansell1†, D. B. Dwyer1*†, S. J. Wood1,2, E. Bora1, W. J. Brewer3, T.M. Profﬁtt3, D. Velakoulis1,
P. D. McGorry3 and C. Pantelis1
1Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia
2School of Psychology, University of Birmingham, UK
3Orygen Youth Health Research Centre, University of Melbourne, Parkville, Victoria, Australia
Background. Whether there are differential effects of ﬁrst-generation antipsychotics (FGAs) and second-generation anti-
psychotics (SGAs) on the brain is currently debated. Although some studies report that FGAs reduce grey matter more
than SGAs, others do not, and research to date is limited by a focus on schizophrenia spectrum disorders. To address this
limitation, this study investigated the effects of medication in patients being treated for ﬁrst-episode schizophrenia or
affective psychoses.
Method. Cortical thickness was compared between 52 ﬁrst-episode psychosis patients separated into diagnostic
(i.e. schizophrenia or affective psychosis) and medication (i.e. FGA and SGA) subgroups. Patients in each group were
also compared to age- and sex-matched healthy controls (n=28). A whole-brain cortical thickness interaction analysis
of medication and diagnosis was then performed. Correlations between cortical thickness with antipsychotic dose and
psychotic symptoms were examined.
Results. The effects of medication and diagnosis did not interact, suggesting independent effects. Compared with con-
trols, diagnostic differences were found in frontal, parietal and temporal regions. Decreased thickness in FGA-treated
versus SGA-treated groups was found in a large frontoparietal region (p<0.001, corrected). Comparisons with healthy
controls revealed decreased cortical thickness in the FGA group whereas the SGA group showed increases in addition
to decreases. In FGA-treated patients cortical thinning was associated with higher negative symptoms whereas increased
cortical thickness in the SGA-treated group was associated with lower positive symptoms.
Conclusions. Our results suggest that FGA and SGA treatments have divergent effects on cortical thickness during the
ﬁrst episode of psychosis that are independent from changes due to illness.
Received 8 June 2013; Revised 19 March 2014; Accepted 16 June 2014; First published online 31 July 2014
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Introduction
The choice of antipsychotic medication to treat a ﬁrst
episode of psychosis may affect medication adherence
(Kahn et al. 2008), symptom remission (Boter et al.
2009) and ultimately patient outcomes (Menezes
et al. 2006). Although second-generation antipsychotics
(SGAs) have become the preferred ﬁrst line of treat-
ment as their side-effects are generally well tolerated
(Abi-Dargham & Laruelle, 2005), low-dose ﬁrst-
generation antipsychotics (FGAs) have been advocated
in some contexts despite the possibility of extrapyrami-
dal symptoms (Carr, 2004). More recently, the decision
to prescribe either drug class has been informed by
an ongoing debate that questions whether FGAs and
SGAs have differential effects on the structure of
the brain independently of the effects of the illness
they are designed to treat (Meyer-Lindenberg, 2011;
Zipursky et al. 2013).
In animal models, chronic administration of both
drug classes results in the same reductions of grey
matter volume primarily of the frontal cortices in rats
(Vernon et al. 2011, 2014) and macaques (Dorph-
Petersen et al. 2005). However, these results are not
replicated in human neuroimaging studies, which re-
port differential effects in the ﬁrst 6 to 12 months
of treatment (Dazzan et al. 2005; Garver et al. 2005;
Lieberman et al. 2005; Girgis et al. 2006; Thompson
et al. 2009; van Haren et al. 2011). Speciﬁcally, FGA
treatment has been associated with lower frontotem-
poral volume (Dazzan et al. 2005) whereas patients
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treated with SGAs show volumetric increases (Garver
et al. 2005; Girgis et al. 2006), and their cumulative
dose is associated with thicker frontal cortices
(van Haren et al. 2011). Similar effects have been re-
ported in the largest randomized controlled trial
conducted to date, which found that the FGA haloper-
idol reduced frontal lobe volume whereas the SGA
olanzapine showed no signiﬁcant reductions over a
period of 6 months (Lieberman et al. 2005; Thompson
et al. 2009). Combined, these results highlight a dis-
crepancy between animal and human research that
has not been resolved.
Further research has indicated that structural brain
differences between patients treated with FGA and
SGA medications is not evident at 12 months
(Thompson et al. 2009), and a more recent study by
Ho et al. (2011) found that differential effects are only
found in the volume of the parietal cortex and white
matter at 7.2 years. In addition, other research has
found that FGAs were associated with an increase,
rather than a decrease, of the anterior cingulate cortex
over 3 years (McCormick et al. 2005). However, the
question still remains as to why frontotemporal differ-
ences are found over periods of 6 to 12 months that
follow treatment for a ﬁrst episode of psychosis, es-
pecially because structural and functional brain differ-
ences at this time can predict long-term outcomes
(Ho et al. 2003; Cahn et al. 2006; Wood et al. 2006;
Gur et al. 2008). This issue could potentially be clariﬁed
by considering the effects of the antipsychotics in dif-
ferent subtypes of ﬁrst-episode psychosis.
Existing research on the differential effects of anti-
psychotics combines patients with affective and
non-affective psychosis (e.g. Lieberman et al. 2005;
Ho et al. 2011), despite evidence of similarities and
differences in brain structure across the conditions
(Morgan et al. 2007). Compared to healthy controls,
patients diagnosed with bipolar disorder show reduc-
tions in paralimbic regions whereas those with chronic
schizophrenia show more extensive changes to limbic,
paralimbic and neocortical structures (Bora et al. 2010;
Ellison-Wright & Bullmore, 2010). In ﬁrst-episode af-
fective and schizophrenia spectrum psychoses, similar
reductions across both conditions compared to controls
have been found in the temporal pole (Kasai et al.
2003a,b), inferior temporal gyrus (Kuroki et al. 2006),
medial frontal gyrus (Janssen et al. 2008), subgenual
cingulate (Koo et al. 2008), prefrontal grey matter
(Wiegand et al. 2004) and in whole-brain measure-
ments (Nakamura et al. 2007). Reductions that are spe-
ciﬁcally associated with ﬁrst-episode schizophrenia
spectrum psychoses have been reported in the insula
(Kasai et al. 2003a,b; Takahashi et al. 2009b), middle
and superior temporal gyri (Kuroki et al. 2006;
Takahashi et al. 2009a), middle frontal gyrus (Janssen
et al. 2008) and cingulate cortices (Koo et al. 2008).
These ﬁndings raise the possibility that medication
and illness type could have independent effects on
the brain, or that there could be an interaction between
them; for example, differential effects may only occur
in patients with schizophrenia due to treatment bias
or underlying pathophysiological processes. Neither
of these possibilities has been previously investigated.
In this study we selected a sample of ﬁrst-episode
schizophrenia and affective psychosis patients (speciﬁ-
cally, depression and bipolar disorder) who were
treated with either FGA or SGA medications based
on prescription guidelines at the time they were
entered into the study. We then established whether
there were cortical thickness differences within the di-
agnostic and medication subgroups when compared to
each other and to a matched healthy control group.
Finally, we conducted a whole-brain interaction analy-
sis to determine whether any of the observed effects
were due to a speciﬁc diagnosis or medication. We
had two alternative hypotheses due to the novelty of
the analysis. On the one hand, both medications and
diagnoses could have exerted independent effects on
cortical grey matter, as has been assumed in previous
research that has not controlled for either factor (e.g.
Takahashi et al. 2009a; Ho et al. 2011). On the other
hand, it was also possible that differential effects of
medications would only be found in patients with
schizophrenia rather than affective psychoses.
Method
Participants
Participants were selected from a well-characterized
cohort of 162 ﬁrst-episode patients and 87 controls
who underwent magnetic resonance imaging (MRI)
scanning between 8 July 1994 and 20 November 1999
(as described in Velakoulis et al. 2006). In brief, the
original cohort was recruited from the Early Psycho-
sis Prevention and Intervention Centre (EPPIC;
Melbourne, Australia), were aged 16 to 30 years, and
were psychotic at the time of the scan as reﬂected
by the presence of at least one symptom (delusions,
hallucinations, disordered thinking or speech, or dis-
organized, bizarre or markedly inappropriate behav-
iour). Subjects received DSM-III-R diagnoses based
on medical record review and either the Royal
Park Multidiagnostic Instrument for Psychosis (MIP;
McGorry et al. 1990) or the Structured Clinical
Interview for DSM-III-R (SCID; Spitzer et al. 1992).
Controls were recruited from similar sociodemo-
graphic areas to patients by approaching ancillary
hospital staff and through advertisements. Patients
were excluded if they had received antipsychotic
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medications prior to their intake into EPPIC, if
they had any history of signiﬁcant head injury,
seizures, neurological diseases, impaired thyroid func-
tion or steroid use, or if they were diagnosed with
alcohol or substance abuse/dependence using the
SCID. Control subjects were excluded based on the
same criteria or if they had a family history of psychi-
atric illness.
At the time of the MRI scan, information on the
current type and dosage of antipsychotic medications
was collected from each participant’s EPPIC medical
records. These data were reviewed for the current
study and participants were selected based on whether
they were prescribed an FGA (e.g. chlorpromazine;
n=41) or an SGA (e.g. risperidone; n=109); participants
with a history of both medication classes (n=5) and
treatment-naïve subjects (n=7) were excluded. Because
of the speciﬁc focus of this study on ﬁrst-episode
schizophrenia versus ﬁrst-episode affective disorders
(i.e. depression or bipolar disorders), we then ex-
cluded participants with other psychosis-related
diagnoses as deﬁned by the SCID or MIP scales, in-
cluding: schizophreniform psychosis (n=57), schizo-
affective psychosis (n=15), delusional disorder (n=3),
substance-induced psychosis (n=4), brief psychosis
(n=6), and psychosis not otherwise speciﬁed (n=12).
We also excluded a further 10 participants due to
poor image quality. Control participants were then
selected by randomly sampling age- and sex-matched
participants from the original cohort. Doses of antipsy-
chotics (apart from olanzapine) were converted to
chlorpromazine equivalents (CPZ-Eq) based on Kane
(1996); that is 5 mg/day triﬂuoperazine, 2mg/day
haloperidol, 2 mg/day ﬂuophenazine, 50mg/day cloza-
pine and 1mg/day risperidone were equivalent to
100mg/day CPZ. Olanzapine was not included in
Kane (1996) because it was a newer antipsychotic
and it was therefore converted based on Woods
(2003), that is 5mg/day olanzapine was equivalent
to 100mg/day CPZ. The Positive and Negative
Syndrome Scale (PANSS; Kay et al. 1987) was also
administered at the time of the scan and was used in
further analysis to characterize the sample.
The ﬁnal sample used in this study comprised 25
FGA-treated subjects [chlorpromazine (n=19), triﬂuo-
perazine (n=3), ﬂupenthixol (n=1), haloperidol (n=1)]
who were admitted between 1994 and 1996 (except
ﬁve who were admitted between 1997 and 1998) and
27 SGA-treated subjects [risperidone (n=17), olanza-
pine (n=6), clozapine (n=4)] who were admitted be-
tween 1997 and 1999 (Table 1). Importantly, patients
were all treated within the same ﬁrst-episode service
(EPPIC) and hence the time difference reﬂected anti-
psychotic prescription guidelines at the time the data
were collected. This reduced the possibility of drug
prescription on the basis of demographic (e.g. age, gen-
der or intelligence) or symptom (e.g. diagnosis and
speciﬁc symptoms) variables that may have biased
the results. Within the antipsychotic medication
groups, there were 27 subjects diagnosed with ﬁrst-
episode schizophrenia psychosis and 25 with affective
psychosis (eight depression/17 bipolar; see Table 1).
Combined, the subsample of this study was not differ-
ent from the original sample of 162 participants
in terms of age (t160=1.24, p=0.22), gender (Z=−0.12,
p=0.91), intelligence (t160=−0.69, p=0.49), age at ﬁrst
admission (t148=1.4, p=0.17) or illness duration
(t158=1.37, p=0.17).
Participants involved in this study have been used
in previous cross-sectional research from this group
investigating medial temporal lobe structures
(Velakoulis et al. 1999, 2006), superior temporal gyri
(Takahashi et al. 2009b), insula cortices (Takahashi
et al. 2009a), anterior cingulate cortices (Fornito et al.
2008) and corpus callosum (Walterfang et al. 2009).
Imaging and pre-processing
MR images were acquired at the Royal Melbourne
Hospital on a 1.5-T Sigma scanner (General Electric
Medical Systems, Australia) using a three-dimensional
volumetric spoiled gradient recalled echo in the
steady-state sequence generating 124 contiguous,
1.5-mm coronal sections. The following imaging para-
meters were used: echo time, 3.3 ms; repetition time,
14.3 ms; ﬂip angle, 30°; matrix size, 256×256; ﬁeld
of view, 24×24 cm matrix; and voxel dimensions,
0.938×0.938×1.5 mm. Images were processed using
the standard FreeSurfer (version 4.5.0) processing pipe-
line. This ﬁrst involved voxel resampling (1mm3),
motion correction, non-uniform intensity normaliza-
tion and removal of the skull. The white-matter bound-
ary was then automatically traced, tessellated and
smoothed at a 20-mm full-width at half-maximum
kernel. The pial boundary was generated from the
white mesh by lateral deformation to the cerebrospinal
ﬂuid. To facilitate group comparisons, FreeSurfer uses
sulcal registration and normalization to Montreal
Neurological Institute (MNI) standard space (Desikan
et al. 2006). Each processed image was reviewed for
pial and white-matter tracing accuracy by a blinded,
trained researcher (B.R.E.A.). FreeSurfer control points
were inserted to extend incorrect white-matter bound-
aries and misclassiﬁed grey matter was deleted.
Images were then reprocessed to improve the accuracy
of the automatic tracing method (Fischl et al. 2004).
Statistical analyses
Clinical and demographic variables were compared
using parametric (ANOVA or t tests) or non-parametric
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Table 1. Demographic results for FGA- and SGA-medicated subject groups
FGA SGA Control Group comparisons
Diagnosis (n females)
FE-SCZ 15 (2) 12 (5) – χ21=1.26, p=0.262
FE-AFF 10 (6) 15 (4)
Total (n females) 25 (8) 27 (9) 28 (11) –
Age (years), mean (S.D.) 21.93 (3.5) 21.95 (3.3) 21.07 (2.5) F1,79=0.698, p=0.501
Admission age (years), mean (S.D.) 21.6 (3.2) 21.4 (3.2) – t49=−0.19, p=0.849
Illness durationa (days), mean (S.D.) 42.36 (83.5) 93.04 (141) – t48=1.55, p=0.129
CPZ-Eq (mg), mean (S.D.) 160.96 (100.7) 251.85 (160.8) – t50=2.42, p=0.019*
Cumulative CPZ-Eq (mg), mean (S.D.) 6250 (9239) 41501 (98481) – t48=1.89, p=0.065
Lateralityb R/L 19/6 22/4, 1 ambidextrous 26/2 χ22=2.914, p=0.233
PANSSc, mean (S.D.)
Positive 22.4 (6.5) 22.4 (5.5) – t37=0.01, p=0.99
Negative 22 (6.8) 21.9 (6.2) – t37=0.06, p=0.95
Generald 41.6 (8.2) 44.3 (7.4) – t36=−1.05, p=0.3
NART, mean (S.D.) 93.11 (13.92) 93.27 (14.33) 101.64 (10.46) ANOVA F1,79=3.867, p=0.025*
FGA v. SGA: F1,50=0.002, p=0.968
FGA v. control: F1,52=6.449, p=0.014*
SGA v. control: F1,54=6.16, p=0.016*
FGA, First-generation antipsychotic; SGA, second-generation antipsychotic; FE-SCZ, ﬁrst-episode schizophrenia; FE-AFF, ﬁrst-episode affective psychosis; CPZ-Eq, equivalent chlor-
promazine dose; R, right; L, left; NART, National Adult Reading Test (a measure of pre-morbid IQ; Nelson & O’Connell, 1978); PANSS, Positive and Negative Syndrome Scale; S.D.,
standard deviation.
a Illness duration measured from time of intake into the Early Psychosis Prevention and Intervention Centre (EPPIC). Data missing for two subjects.
b Ambidextrous patient excluded for the χ2 test.
c Analysis based on available data for 15 FGA-treated subjects and 24 SGA-treated subjects.
d Data were not available for one FGA-treated subject.
* Signiﬁcant at p<0.05.
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(χ2) tests where appropriate. Between-group differ-
ences in cortical thickness were estimated using the
FreeSurfer query design estimate contrast (QDEC;
http://surfer.nmr.mgh.harvard.edu) interface. General
linear models were used to estimate thickness differ-
ences at each vertex of both hemispheres with a
threshold of p<0.001 to derive spatially precise and
statistically robust clusters of signiﬁcant vertices. For
each cluster, the family-wise error was then corrected
using the FreeSurfer Monte-Carlo approach as de-
scribed previously (Hagler et al. 2006). This procedure
estimates the probability of observing a cluster of
equal or greater spatial extent from a null distribution
of cluster sizes generated from 10000 simulations of
random data. Statistical signiﬁcance was then declared
if the cluster probability was p<0.05. The cortical label,
Talairach coordinates, cluster area (mm2), effect size
and cluster p value were then tabulated.
Three sets of planned comparisons were conducted
to identify differences between diagnoses and medica-
tions before conducting analyses of interactions. First,
pair-wise comparisons were conducted between all
combinations of the ﬁrst-episode schizophrenia partici-
pants, ﬁrst-episode affective participants and healthy
controls to determine differences between the diagnos-
tic groups. Second, comparisons were conducted be-
tween all combinations of groups treated with FGAs,
SGAs and controls to determine differences between
the medication classes. Third, the interaction between
the diagnosis and medication type was assessed. To
visualize similarities and differences of the compari-
sons within each set, signiﬁcant results (cluster thresh-
old, p<0.05) were binarized, colour coded and
overlayed onto a standard average brain included in
the FreeSurfer software (fsaverage). Overlap between
comparisons was represented as a linear combination
of the colours (e.g. overlap between green and red
was represented as yellow).
To further investigate the relationship between anti-
psychotic use and cortical thickness changes, dose–
response relationships were assessed. Spearman’s
rank correlations were calculated between average
thicknesses for each signiﬁcant cluster of the FGA–
SGA comparison, with the cumulative medication
dose calculated by multiplying daily CPZ-Eq dosage
by the number of days from each patient’s admission
(and therefore treatment) to the date of the MRI scan.
To investigate the relationship to clinical symptoms,
Spearman’s rank correlations were then calculated be-
tween the thickness values of the same clusters and the
positive, negative and general PANSS scores. Finally,
because mood stabilizers are known to increase grey-
matter volume (Bora et al. 2010; Lyoo et al. 2010),
patients taking lithium (n=2) were removed from the
SGA-medicated cohort, and the analysis of cortical
thickness difference between medication groups was
repeated.
Results
Demographics
No differences were found between FGA- and
SGA-treated patient groups in diagnosis, age, sex, or
estimated pre-morbid intelligence (Table 1; Nelson &
O’Connell, 1978). Analysis of the PANSS also did not
reveal any differences in positive, negative or general
psychotic symptoms (Table 1). However, differences
were found for dosage, with the SGA group exhibit-
ing a higher mean CPZ-Eq. The control group was
matched for age and sex but had higher pre-morbid
intelligence when compared to patients (Table 1).
Diagnostic differences in cortical thickness
The ﬁrst-episode schizophrenia group exhibited
decreased thickness compared to controls in frontal,
parietal, temporal and occipitotemporal regions
(Table 2; Fig. 1). These differences were most pro-
nounced in the prefrontal regions of the right caudal
middle frontal gyrus (Z=−5.6, p<0.001) and the
medial surface of the right superior frontal gyrus
(Z=−5.4, p<0.001). By contrast, the comparison of
ﬁrst-episode affective psychosis with controls only
revealed reductions in two spatially smaller areas:
one in the right inferior parietal lobe and the other
mainly located in the right cingulate sulcus.
Comparison of diagnostic subgroups did not reveal
signiﬁcant differences at cluster-corrected levels, but
when the statistical criterion for signiﬁcance was
relaxed to a vertex-wise level of p<0.05 for exploratory
purposes, the schizophrenia subgroup demonstrated
reduced thickness in large clusters across frontal and
parietal regions (Supplementary Fig. S1).
Medication differences in cortical thickness
Compared to control participants, the FGA subgroup
demonstrated reduced cortical thickness of the right
middle frontal and superior frontal gyri whereas the
SGA subgroup exhibited reduced thickness in mostly
non-overlapping regions of the right inferior parietal,
superior frontal and fusiform gyri (Table 2; Fig. 2).
Furthermore, those medicated with SGAs also dis-
played increased cortical thickness compared with con-
trols of the left precentral and right postcentral gyri,
but no increases were detected in the FGA group
(Table 2).
Comparison of the medication subgroups revealed
large clusters of reduced cortical thickness associated
with the FGA group in bilateral regions that included
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the superior frontal, pre- and postcentral gyri and peri-
calcarine cortices. Of note, these regions did not over-
lap substantially with those found in comparisons
with control participants, with two exceptions. First,
the most pronounced difference between the medi-
cation groups was located in the left precentral gyrus
(Z=−7.2, p<0.001), which was in a similar location
to the peak associated with increased cortical thickness
in the SGA group compared to controls (Table 2).
Second, a cluster was found in the right middle frontal
gyrus where the FGA group demonstrated reduced
cortical thickness compared to the SGA patients and
controls (Fig. 2, yellow cluster).
To further investigate the relationship to controls in
clusters derived from the medication subgroup com-
parison, we extracted the mean thickness estimates of
each cluster across participants. We then plotted
these estimates to compare the groups graphically,
and tested for signiﬁcant differences with controls
using t tests at an exploratory level of p<0.05
(Fig. 2a–f). Visual comparison of the groups shows
that the control group was interposed between the
FGA subgroup, which demonstrated the lowest thick-
ness estimates, and the SGA subgroup, which demon-
strated the highest estimates. Statistical comparisons
demonstrated signiﬁcantly increased thickness in the
SGA group compared to controls across all clusters,
and decreased thickness of the right superior frontal
and postcentral gyri in the FGA group.
Interaction analyses
No signiﬁcant interactions at cluster-corrected levels
were found, suggesting that the effects of diagnosis
Table 2. Cortical thickness differences of diagnostic, medication and control groups
Cluster location
Talairach coordinates of
peak difference (x,y,z)
Effect size of
peak difference
(z score)
Cluster size
(mm2)
Cluster
probability
(p value)
Diagnostic differences
Scz<Ctrl
Right caudal middle frontal 34 14 31 −5.6 1363 <0.001
Right superior frontal 10 12 42 −5.4 1347 <0.001
Right supramarginal 43 −28 23 −4.1 368 0.03
Left superior frontal −7 4 56 −4.3 452 0.01
Left lateral occipital −47 −71 12 −4.2 437 0.01
Left parahippocampal −20 −40 −7 −3.5 320 0.03
Aff<Ctrl
Right inferior parietal 38 −62 16 −4.0 533 0.006
Right superior frontal 13 23 30 −3.8 402 0.02
Medication differences (decreases)
FGA<Ctrl
Right rostral middle frontal 39 26 31 −5.1 853 <0.001
Right superior frontal 8 12 52 −4.5 581 0.004
SGA<Ctrl
Right inferior parietal 37 −58 18 −6.6 1998 <0.001
Right superior frontal 12 27 30 −5.2 1209 <0.001
Right fusiform 42 −47 −9 −4.3 585 0.004
FGA<SGA
Left precentral −33 −17 45 −7.2 971 <0.001
Left pericalcarine −13 −81 10 −5.3 1165 <0.001
Left superior frontal −19 30 46 −4.7 952 <0.001
Right postcentral 39 −17 41 −6.9 4319 <0.001
Right superior frontal 16 37 41 −6.0 855 <0.001
Right pericalcarine 5 −75 15 −5.3 1123 <0.001
Medication differences (increases)
SGA>Ctrl
Left precentral −34 −21 43 4.8 429 0.01
Right postcentral 39 −18 42 3.7 408 0.02
Scz, Schizophrenia; Ctrl, control; Aff, affective psychosis; FGA, ﬁrst-generation antipsychotic; SGA, second-generation
antipsychotic.
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and medication were independent. However, because
of the reduction in statistical power associated with
an investigation of interaction effects in a sample of
this size (i.e. the a priori power to detect an interaction
effect was calculated as 0.75), we lowered the primary
threshold of signiﬁcance to an uncorrected level of
p=0.05. The results demonstrated small and spatially
diffuse regions of signiﬁcance that probably repre-
sented false-positive results given the large number
of comparisons (Supplementary Fig. S3). Combined,
there was very little evidence for drug×medication
interaction effects.
Correlation analyses
Given the aim of the study to investigate differences
between FGA and SGA treatment, we focused on
dose–response analysis of the clusters derived from
the medication subgroup comparison. A higher cumu-
lative dose was signiﬁcantly associated with reduced
cortical thickness in the left superior frontal cortex
of those treated with FGA medications (ρ=−0.46,
p=0.018; Fig. 3), but not with those treated with
SGAs (Supplementary Table S1). Correlations between
total symptom scores on the PANSS and cortical thick-
ness in the same clusters across the groups did not
reveal signiﬁcant associations at uncorrected levels
(p>0.05; Supplementary Table S2). However, dividing
the sample into treatment groups revealed that
reduced positive symptoms were associated with
increased thickness of the left superior frontal gyrus
in SGA-medicated subjects (ρ=−0.52, p=0.012), and
reduced negative symptoms were associated with
increased thickness of the left pericalcarine (ρ=−0.62,
p=0.014), right pericalcarine (ρ=−0.61, p=0.015) and
right postcentral gyrus (ρ=−0.63, p=0.012) in FGA-
medicated subjects (Supplementary Table S2). Com-
bined, these results suggest that reduced symptoms
are associated with a thicker cortex, but also that the
effects are speciﬁc to each group.
Exclusion of lithium-treated individuals
The exclusion of the two patients using lithium had no
appreciable effect on the comparison of the FGA and
SGA subgroups (Supplementary Fig. S2).
Discussion
In this study we examined structural differences in
a group of ﬁrst-episode patients with either a schizo-
phrenia or affective diagnosis, and also the effects of
FGAs versus SGAs within an average of 3 months fol-
lowing intake. Our results indicate that FGA and SGA
medications have divergent effects on cortical thick-
ness that are independent of diagnosis-related changes.
Thus, both FGAs and SGAs were associated with
cortical thickness differences regardless of diagnosis
in these ﬁrst-episode patients. Analysis of each treat-
ment group compared with controls demonstrated
that FGAs were associated with decreased thickness
in frontal regions whereas SGAs were associated
with increased thickness of pre- and postcentral gyri
in addition to decreased thickness of medial frontal,
parietal and fusiform areas.
The main focus of this study was the comparison of
the two treatment conditions. These analyses indicated
that a large area of the frontoparietal region showed
decreased thickness in the FGA compared to the
SGA group, particularly involving the bilateral
superior frontal gyri, bilateral pericalcarine gyri, left
precentral gyrus and right postcentral gyrus.
Comparison with controls within these regions indi-
cated that FGA-treated patients tended to show
decreased cortical thickness whereas the SGA group
showed increases. Correlational analysis using esti-
mates from the same clusters indicated that increased
FGA dose was associated with reduced cortical
Fig. 1. Comparisons of diagnostic subgroups. Brain surface
maps show statistically signiﬁcant areas of reduced cortical
thickness (cluster-wise probability, p<0.05) derived from
pair-wise group comparisons. Each comparison is colour
coded and overlap between clusters is represented as a
linear combination of comparison colours. Reduced cortical
thickness was found in the ﬁrst-episode schizophrenia (Scz)
group compared to controls (Ctrl; green areas) in the right
inferior frontal gyrus, bilateral medial superior frontal gyri
and left temporo-occipital cortex. Reduced thickness of the
affective psychosis subgroup (Aff; blue) was found in the
right temporo-occipital region and in a small area of
the right cingulate sulcus. No signiﬁcant differences were
found when comparing schizophrenia and affective
subgroups (red).
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thickness of the superior frontal cortex. Furthermore,
in the FGA-treated patients, cortical thinning was
associated with higher negative symptom scores.
By contrast, increased cortical thickness in the SGA-
treated group was associated with lower positive
symptom scores.
Diagnostic differences
Compared to control participants, the ﬁrst-episode
schizophrenia psychosis group exhibited reduced
thickness in large clusters of the inferior frontal gyrus
and medial surface of the superior frontal gyrus,
whereas the ﬁrst-episode affective psychosis group
demonstrated reductions in the inferior parietal lobe
and the cingulate sulcus. As in previous research
(e.g. Kuroki et al. 2006), comparisons between the diag-
nostic groups did not reveal signiﬁcant differences.
Our results support previous research in showing
more pronounced differences in patients with ﬁrst-
episode schizophrenia spectrum psychoses in frontal
regions (Wiegand et al. 2004; Janssen et al. 2008), but
they did not replicate previous ﬁndings in the insula
(Kasai et al. 2003a,b; Takahashi et al. 2009a), middle
and superior temporal gyri (Kuroki et al. 2006;
Takahashi et al. 2009a) or cingulate cortices (Koo et al.
2008). Furthermore, unlike in most previous research,
we did not ﬁnd overlapping patterns of reduced corti-
cal thickness that generalized across both schizo-
phrenia and affective groups in the temporal pole
(Kasai et al. 2003a,b), inferior temporal gyrus
Fig. 3. Dose–response relationship. Relationship between
cumulative ﬁrst-generation antipsychotic (FGA) dose and
average cortical thickness of the left superior frontal cortex
cluster identiﬁed in Fig. 2 and Table 2. Note log scale of the
x axis.
Fig. 2. Comparisons of medication subgroups. Brain surface maps (left) show statistically signiﬁcant (cluster-wise probability,
p<0.05) areas of reduced cortical thickness in comparisons of: subgroups treated with ﬁrst-generation antipsychotics (FGAs)
compared to second-generation antipsychotics (SGAs; red clusters), the FGA subgroup compared to control participants (Ctrl;
green clusters), and the SGA subgroup compared to control participants (blue clusters). Overlap of clusters is represented as a
linear combination of colours from pair-wise comparisons (see colour wheel on bottom left). Results demonstrated large areas
of reduced cortical thickness in the subgroup treated with FGAs in superior frontal, pre- and postcentral and pericalcarine
gyri. Compared to control participants, reductions were found in the FGA subgroup in the right superior lateral and medial
frontal cortex, and in the SGA group in the right cingulate and temporo-occipital regions. Further investigation of the mean
thickness from the clusters of the FGA versus SGA subgroups (right plots; a–f) demonstrated that the mean cortical thickness
of the control group was interposed between patients treated with FGAs and those treated with SGAs in the following
regions: (a) left superior frontal gyrus, (b) left precentral gyrus, (c) left pericalcarine gyrus, (d) right superior frontal gyrus,
(e) right postcentral gyrus and (f) right pericalcarine gyrus. t tests with control group comparison: ¤, p<0.05, † p<0.01,
‡ p<0.001.
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(Kuroki et al. 2006), medial superior frontal gyrus
(Janssen et al. 2008) or subgenual cingulate (Koo et al.
2008). Given that previous research has not controlled
for medication class, it is possible that the more cir-
cumscribed results in this study represent more
speciﬁc effects of each illness, for example overlapping
patterns in previous research could be due to the ef-
fects of either FGA or SGA medications. However, it
should also be noted that the partial convergence
with previous research could be due to other factors,
such as the methodology or speciﬁc sample used here.
FGAs
The results of this study support previous research
showing decreased frontal grey matter in FGA- relative
to SGA-medicated patients (Dazzan et al. 2005; Garver
et al. 2005; Lieberman et al. 2005; Girgis et al. 2006;
Thompson et al. 2009; van Haren et al. 2011). The
ﬁnding that increased cumulative FGA dose correlated
with reduced cortical thickness in the superior frontal
gyrus is in line with previous ﬁndings of a similar re-
lationship in the left precentral gyrus (van Haren
et al. 2011). Notably, compared to healthy controls,
decreased thickness was also observed in post-hoc com-
parisons in the left superior frontal gyrus and right
postcentral gyrus, whereas whole-brain comparisons
revealed clusters of reduced thickness in the medial
superior frontal gyrus and middle frontal gyrus. In ad-
dition, we found that reduced cortical thickness was
associated with increased negative symptoms in bilat-
eral pericalcarine cortices and the right postcentral
gyrus. Combined, these results suggest that FGA med-
ications reduce cortical thickness during a ﬁrst episode
of psychosis and that such reductions may be asso-
ciated with higher negative symptoms.
The pattern of thickness difference found in this
study was most similar to the results of Thompson
et al. (2009), who found frontoparietal reductions
with FGA treatment during a longitudinal randomized
controlled trial in ﬁrst-episode schizophrenia. These
effects might occur because of medication-induced ef-
fects on neuropil (i.e. unmyelinated axons, dendrites
and glial processes), neuronal bodies or brain haemo-
dynamics. First, FGA-induced reductions in neuropil
have been evidenced in rodents (reviewed in Harrison,
1999; Castillo-Gómez et al. 2008), and as such a similar
effect may have resulted in the reductions of cortical
thickness found here, and also increases in neuronal
density in post-mortem brains of FGA-treated schizo-
phrenia patients (Selemon et al. 1998). Second, thick-
ness may decrease due to neuronal cell loss, in light
of evidence showing that haloperidol treatment can re-
sult in oxidative stress in rodent brains (Rienke et al.
2004) and apoptosis in neuronal cultures (Noh et al.
2000). Third, a reduction in blood ﬂow to the frontal
lobes has been associated with FGA use (Miller et al.
2001), which may theoretically affect thickness
(Dazzan et al. 2005; McClure et al. 2008). Delineating
between these possibilities during a ﬁrst episode of
psychosis could thus be a focus of future research.
Alternatively, it should be noted that the fronto-
parietal thickness differences found in this study
could be because FGA-medicated patients received a
lower standardized dose (CPZ-Eq) when compared
to those treated with SGAs (Table 1); for example,
insufﬁcient treatment of the FGA group may have ex-
posed an underlying disease process related to cortical
atrophy. However, similar effects to those found in
this study have also been displayed in previous re-
search with similar cumulative doses of each medi-
cation (e.g. Dazzan et al. 2005; Lieberman et al. 2005;
Thompson et al. 2009), a dose–response relationship
with FGA treatment was found, symptoms of the
patients did not differ between the medication groups,
and we did not ﬁnd an interaction between medication
and diagnosis.
SGAs
Patients treated with SGAs displayed greater cortical
thickness than patients treated with FGAs in fronto-
parietal regions, in accordance with previous longi-
tudinal research (Garver et al. 2005; Lieberman et al.
2005; Molina et al. 2005; Girgis et al. 2006; Thompson
et al. 2009). Increased thickness was also found in com-
parisons of the SGA group with controls in post-hoc
analyses, and also for two clusters in the pre- and post-
central sulci at a whole-brain level. Of note, there
has been only one study to our knowledge that has
shown increases in cortical volume with SGA treat-
ment in comparisons with controls (Molina et al.
2005), and thus these results may represent an import-
ant addition to previous research. Furthermore, the
current study has also demonstrated a novel corre-
lation between increased thickness of the superior fron-
tal gyrus and reductions in positive symptoms.
The lack of an interaction with diagnosis, coupled
with observations of increased thickness compared to
controls, suggests that SGAs may increase grey matter
measurements rather than suppressing any illness-
related effects that may reduce cortical grey matter.
In a similar way that FGA treatment may be associated
with decreases of the neuropil, these ﬁndings may sug-
gest that SGAs result in increases of the neuropil.
Support for this hypothesis comes from rodent studies
ﬁnding that SGA treatment is associated with both
increased neuropil density in the prefrontal cortex
(Maćkowiak et al. 2009) and increased expression levels
for proteins implicated in synaptogenesis (Chiba et al.
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2006; Maćkowiak et al. 2009). Furthermore, brain-
derived neurotrophic factor, which stimulates synapto-
genesis in rodents (Aguado et al. 2003), is increased
both in rat neurons in vitro after SGA treatment
(Tan et al. 2007) and in the serum of SGA-treated
ﬁrst-episode patients (González-Pinto et al. 2010).
Thus, our ﬁndings support the notion that medication
classes have opposite effects on cortical thickness that
may be mediated through differing impact on synapto-
genesis at the same cortical sites.
However, although opposite changes to neuropil is
a compelling hypothesis to describe differential effects
of FGA and SGA medications, other hypotheses
should be noted. First, SGA-mediated increases in
cortical thickness may be related to blood ﬂow changes
as SGAs can normalize blood ﬂow deﬁcits associated
with ﬁrst-episode psychosis (Pardo et al. 2011).
However, although normalized blood ﬂow may ex-
plain increases of thickness relative to FGA-medicated
ﬁrst-episode patients, this does not explain the absol-
ute increase relative to controls. Second, it is possible
that the metabolic disturbances that arise from SGA
treatment may increase cortical thickness through
changes to tissue perfusion, fat and water content
(Weinberger & McClure, 2002; Mondelli et al. 2013).
However, if these secondary metabolic changes were
the cause of thickness increases then it is difﬁcult to de-
scribe how they would relate to decreases in positive
symptoms as we found in the superior frontal gyrus
of SGA-medicated subjects.
A more substantial challenge to the neuropil hypoth-
esis of differential medication effects is that we also
found decreased thickness with SGA treatment com-
pared to controls in the inferior parietal, superior
frontal/anterior cingulate and fusiform gyri. This
result differs from previous research because similar
decreases associated with SGA treatment have only
been reported in previous longitudinal research,
when structural brain changes could be compounded
by intervening factors (McCormick et al. 2005; Ho
et al. 2011). In addition, although animal research
does report volumetric decreases associated with
SGA treatments over short time periods (Dorph-
Petersen et al. 2005; Vernon et al. 2011, 2014), they are
not localized to speciﬁc areas such as we found here.
Taken together, these novel ﬁndings may suggest
that, although SGA increases are more common during
short-term treatment, decreases may be localizable to
certain brain regions, such as the anterior cingulate
cortex.
Implications
The results of this study demonstrate that the effects of
psychotic illness and medication on cortical thickness
are separable during a ﬁrst episode of psychosis.
Concerning diagnostic differences, the results raise
the possibility that previously reported overlapping
patterns of cortical deﬁcit in schizophrenia and affect-
ive psychoses might be attributable to medication
effects. Concerning medication differences, this re-
search mainly highlights that FGAs may decrease,
whereas SGAs increase, cortical thickness in fronto-
parietal brain regions. An intriguing hypothesis from
our ﬁndings, showing that increased thickness was
associated with reduced symptoms across mediation
types, is that treatments maximizing cortical thickness
may have positive beneﬁts on symptoms. Furthermore,
these changes may be particularly relevant to consider
during the earliest stages of illness as studies have
shown that grey matter indices at this time predict
long-term outcomes (Ho et al. 2003; Cahn et al. 2006;
Wood et al. 2006; Gur et al. 2008).
Limitations
Although every attempt was made to control for het-
erogeneous patient differences that are inherent in
most clinical samples, the following limitations should
be kept in mind. First, although this study did not ﬁnd
an interaction between ﬁrst-episode schizophrenia and
affective psychoses, the interaction analyses were mar-
ginally underpowered and analysis with larger groups
is needed. Second, the simpliﬁed FGA/SGA dichotomy
in this study belies the pharmacological complexity
of each drug included within these categories; for
example, the FGA drugs haloperidol and chlorproma-
zine have differing neurotransmitter receptor-binding
proﬁles, which may have inﬂuenced the results.
Third, two neuroleptic-naïve ﬁrst-episode schizo-
phrenia and affective psychosis cohorts would have
been preferable to using healthy control subjects to di-
rectly address the issue of interactions between illness
and medication. Finally, the conclusions of this study
can only be interpreted within the context of short-
term ﬁrst-episode treatment based on a cross-sectional
sample. Further research that longitudinally investi-
gates the effects of antipsychotic class in different psy-
chosis subtypes using balanced randomized controlled
designs is needed.
Conclusions
Our results suggest that FGA and SGA treatments
have divergent effects on cortical thickness during
the ﬁrst episode of psychosis that are independent
from changes due to illness.
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